Browse by author
Lookup NU author(s): Dr Paul Brennan
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© The Author(s) 2024. Background: The CanRisk tool, which operationalises the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is used by Clinical Geneticists, Genetic Counsellors, Breast Oncologists, Surgeons and Family History Nurses for breast cancer risk assessments both nationally and internationally. There are currently no guidelines with respect to the day-to-day clinical application of CanRisk and differing inputs to the model can result in different recommendations for practice. Methods: To address this gap, the UK Cancer Genetics Group in collaboration with the Association of Breast Surgery and the CanGene-CanVar programme held a workshop on 16th of May 2023, with the aim of establishing best practice guidelines. Results: Using a pre-workshop survey followed by structured discussion and in-meeting polling, we achieved consensus for UK best practice in use of CanRisk in making recommendations for breast cancer surveillance, eligibility for genetic testing and the input of available information to undertake an individualised risk assessment. Conclusions: Whilst consensus recommendations were achieved, the meeting highlighted some of the barriers limiting the use of CanRisk in clinical practice and identified areas that require further work and collaboration with relevant national bodies and policy makers to incorporate wider use of CanRisk into routine breast cancer risk assessments.
Author(s): Tsoulaki O, Tischkowitz M, Antoniou AC, Musgrave H, Rea G, Gandhi A, Cox K, Irvine T, Holcombe S, Eccles D, Turnbull C, Cutress R, Archer S, Hanson H, Andreou A, Badran A, Bartlett M, Berlin C, Binysh K, Brennan P, Cleaver R, Corbett G, Davidson R, DeSouza B, Evers R, Ficorella L, Fitzgerald S, Forman A, Gilbert F, Gold R, Greville-Heygate S, Hamilton S, Hammond C, Hart R, Hawkes L, Hayward J, Holliday D, Howell A, Hutchison G, Jenkins J, Jewell R, Kavanaugh G, Kemp Z, Kiesel V, Kumar A, Lalloo F, Miedzybrodzka Z, Murray J, Nisbet S, Ogunleye D, Paramasivam A, Searle C, Shaw A, Sheridan E, Side L, Smith K, Speight B, Teh W, Thorpe E, Whaite A, Wilkinson L, Wilkinson S, Woodward ER, Youngs A
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 2024
Volume: 130
Pages: 2027-2036
Print publication date: 29/06/2024
Online publication date: 04/06/2024
Acceptance date: 21/05/2024
Date deposited: 19/06/2024
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
Publisher: Springer Nature
URL: https://doi.org/10.1038/s41416-024-02733-4
DOI: 10.1038/s41416-024-02733-4
Data Access Statement: The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
Altmetrics provided by Altmetric
